Goin Kathleen 4

What Happened Kathleen Goin, Chief Operating Officer of Palvella Therapeutics (PVLA), received a grant (derivative award) covering 48,956 shares on February 5, 2026. The Form 4 reports an acquisition price of $0.00 for the award. Per the filing footnote, the award is an option-like grant that vests and becomes exercisable in equal monthly installments over 48 months, subject to Goin’s continued service.

Key Details

• Transaction date: February 5, 2026; Form 4 filed February 9, 2026 (timely filing).
• Transaction type/code: A — Grant / award (derivative).
• Amount: 48,956 shares; reported acquisition price: $0.00.
• Vesting/exercisability: Equal monthly installments over 48 months beginning Feb 5, 2026, contingent on continuous service (per footnote).
• Shares owned after transaction: Not specified in the provided summary of this filing.
• No 10b5-1 plan, tax-withholding, or cashless-exercise details disclosed in this record.

Context This filing documents a compensation grant to an executive rather than an open-market buy or sell. Such awards are commonly part of executive pay and do not necessarily signal immediate insider bullish or bearish sentiment. Because the award vests over four years and is described as becoming “exercisable,” it functions like a stock option that the insider must wait to vest before exercising.